预测贝希特综合征中对因弗利西马布和干扰素α的反应:来自BIO-BEHÇET的随机对照试验的探索性分析
Robert J Moots1,2, Farida Fortune3, Richard Jackson4
1Faculty of Health, Social Care and Medicine, Edge Hill University, Ormskirk, UK.
Rheumatology and immunology research
|July 3, 2025
概括
一种新的代谢生物标志物可以预测Behçet综合征患者对Infliximab的反应. 来自BIO-BEHÇET的试验的这一发现为这种罕见疾病的个性化生物疗法提供了希望.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 尽管证据有限,但对于贝切特综合征 (BS) 仍使用生物疗法.
- 在BS管理中缺乏治疗反应的预测生物标志物.
- 在BIO-BEHÇET'S试验中,infliximab和干扰素-α2a对活性BS进行了比较.
研究的目的:
- 为了比较Infliximab与干扰素-α2a在贝希特综合征中的疗效.
- 确定潜在的生物标志物,包括遗传和代谢标志物,用于预测BS患者的药物反应.
主要方法:
- 一项随机对照试验 (BIO-BEHÇET'S) 涉及79名活跃的BS患者.
- 患者接受了infliximab或干扰素-α2a,在12周和24周进行了随访.
- 探索性分析包括IFNL3/IFNL4中的单核酸多态 (SNPs) 和通过NMR光谱学进行尿路代谢.
主要成果:
- 遗传分析表明,IFNL3变体 (rs4803221,rs7248668) 与干扰素-α2a反应之间存在潜在的关联,尽管在校正后没有统计学意义.
- 泌尿代谢分析确定了与对infliximab的代谢反应相关的潜在标志物.
结论:
- BIO-BEHÇET的试验表明一种潜在的新型代谢生物标志物,用于预测Behçet综合征中的Infliximab反应.
- 需要进一步的研究来描述特定的代谢物,并在未来的临床试验中验证这些发现.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
239
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
239
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
277
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
277
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
430
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
430


